Video-Assisted Thoracoscopic Surgery (VATS)

Video-assisted thoracoscopic surgery (VATS) is a minimally invasive surgical technique used to examine, biopsy, and in some cases remove tissue inside the chest cavity. For patients facing a possible pleural mesothelioma diagnosis, VATS is often the procedure that delivers a definitive answer. It's performed through two or three small incisions, each less than an inch long, rather than the large opening required by traditional open chest surgery (thoracotomy). A tiny camera called a thoracoscope transmits live video to a monitor, guiding the surgeon's instruments without the need to spread or cut through the ribs.

The technique was refined in the early 1990s, building on earlier thoracoscopic work done in Europe. According to the National Cancer Institute, VATS is now a standard approach across thoracic oncology for both diagnosis and treatment of diseases including mesothelioma, lung cancer, and malignant pleural effusion. The procedure can be performed under general anesthesia and typically takes between one and three hours, depending on its complexity.

For mesothelioma patients specifically, VATS serves two critical roles. First, it allows surgeons to obtain large, well-preserved tissue samples from the pleural lining, which are essential for the detailed pathological analysis needed to distinguish mesothelioma from other malignancies. Second, in carefully selected patients with early-stage disease, VATS can be part of a curative or cytoreductive surgical strategy. As one thoracic oncologist summarized it: "VATS changed what we could offer patients. We went from procedures that took weeks to recover from to ones where people are home in a few days."

Recovery from VATS is substantially faster than from open thoracotomy. A 2019 review published in the Journal of Thoracic Disease found that VATS patients experienced significantly less postoperative pain, shorter chest tube duration, and reduced rates of pulmonary complications compared to patients who underwent conventional open surgery. For a population that is often elderly and has compromised lung function from asbestos exposure, those differences are clinically meaningful.

VATS procedures aren't a single operation. They encompass a range of interventions, each tailored to a specific clinical goal. Understanding which type a patient needs depends on the stage of disease, the location of suspected tissue, and the overall surgical plan.

• Diagnostic VATS (Thoracoscopic Biopsy): The most common application in mesothelioma workups. The surgeon inserts the thoracoscope and retrieves multiple pleural biopsies under direct visualization. This approach yields far more tissue than CT-guided needle biopsy and is particularly important when immunohistochemical staining or electron microscopy is needed to confirm a mesothelioma subtype.
• VATS Pleurodesis: Used to manage recurrent malignant pleural effusion. After draining the fluid, the surgeon introduces talc or another sclerosing agent to fuse the pleural layers and prevent fluid from reaccumulating. This is primarily a palliative intervention.
• VATS Pleurectomy/Decortication (P/D): A more extensive procedure in which the surgeon removes the diseased pleural lining while preserving the lung. When performed via VATS, it is sometimes called minimally invasive P/D or uniportal VATS P/D. According to a 2021 study in Annals of Thoracic Surgery, centers with high VATS volume have reported comparable oncologic outcomes to open P/D with significantly reduced blood loss.
• VATS Lobectomy: Removal of an entire lobe of the lung, most commonly used in non-small cell lung cancer but occasionally relevant in mesothelioma cases where tumor has invaded adjacent lung tissue.
• Robotic-Assisted VATS (RATS): A variant using robotic arms controlled by the surgeon from a console. The da Vinci Surgical System is the most widely used platform. Robotic assistance provides enhanced dexterity and three-dimensional visualization, though evidence of superior outcomes over conventional VATS in mesothelioma specifically remains under investigation.

VATS is generally safer than open chest surgery, but it isn't without risk. Patients and families should understand which factors influence the likelihood of complications before consenting to the procedure.

Pulmonary function is the most critical variable. Because VATS requires one-lung ventilation during surgery (the operative lung is deflated to give the surgeon room to work), patients with severely reduced lung capacity may not tolerate the procedure safely. Pulmonary function tests, including FEV1 and DLCO measurements, are routinely ordered before surgery. According to the Mayo Clinic, an FEV1 below 40% of predicted value substantially increases operative risk. Many mesothelioma patients have pre-existing restrictive lung disease from decades of asbestos exposure, making this evaluation especially important.

Other factors that increase procedural risk include: prior chest surgery or radiation (which can create adhesions that make VATS technically difficult or impossible), active infection, uncontrolled bleeding disorders, and cardiovascular disease that limits the ability to tolerate general anesthesia. Obesity can also complicate positioning and instrument access. Surgeons at high-volume thoracic centers will assess these variables through a multidisciplinary preoperative evaluation that typically includes cardiology, pulmonology, and anesthesiology input.

Conversion to open thoracotomy occurs in roughly 2% to 5% of VATS cases, according to data from the Society of Thoracic Surgeons national database. This happens when bleeding, dense adhesions, or unexpected anatomical findings make it unsafe to continue with the minimally invasive approach. Patients should be counseled about this possibility before surgery.

Imagine you've had weeks of worsening shortness of breath, and a CT scan shows fluid around your right lung and thickening of the pleural lining. Your pulmonologist suspects mesothelioma, but CT-guided needle biopsies have come back inconclusive twice. This is exactly the scenario where VATS becomes the next, necessary step.

In the context of mesothelioma diagnosis, VATS is considered the gold standard for obtaining tissue when less invasive methods have failed or when the volume and quality of tissue needed for full pathological characterization is unlikely to be achieved by other means. The pleural lining in mesothelioma grows in a diffuse, sheet-like pattern rather than forming a discrete nodule, which makes needle biopsy notoriously unreliable. A 2017 analysis published in Lung Cancer found that CT-guided biopsy had a sensitivity of approximately 77% for pleural malignancy, compared to over 95% for thoracoscopic biopsy.

During a diagnostic VATS procedure, the surgeon takes multiple biopsies from different regions of the pleura under direct camera guidance. This spatial sampling is critical because mesothelioma subtypes, including epithelioid, sarcomatoid, and biphasic, can be distributed unevenly across the pleural surface. An accurate subtype determination directly affects prognosis and treatment planning. The tissue is sent to pathology for hematoxylin and eosin staining, immunohistochemical panels, and sometimes electron microscopy or molecular profiling. Results typically return within five to seven business days.

VATS also provides the opportunity to assess disease extent visually. The surgeon can evaluate whether the tumor has spread to the diaphragm, pericardium, or mediastinal structures, information that helps stage the disease and determine whether a patient is a candidate for aggressive surgical resection. This intraoperative staging information complements what CT and PET imaging can reveal.

Beyond diagnosis, VATS plays an active therapeutic role in mesothelioma management, particularly at centers that specialize in thoracic oncology. The extent of surgery possible through VATS depends on tumor burden, patient fitness, and institutional expertise.

Pleurectomy/decortication (P/D) performed via VATS has gained traction as an alternative to the more radical extrapleural pneumonectomy (EPP), which removes the entire lung along with surrounding structures. A 2022 multicenter analysis in JAMA Oncology supported lung-sparing surgery as the preferred surgical approach for eligible patients, citing comparable survival data with significantly better postoperative quality of life. When P/D can be completed through VATS portals rather than a full thoracotomy incision, recovery is further accelerated, which matters enormously for patients who need to begin or continue systemic chemotherapy.

VATS is also used to deliver hyperthermic intrathoracic chemotherapy (HITHOC) in some specialized centers. After surgical debulking, heated chemotherapy solution (commonly cisplatin) is circulated through the chest cavity for 60 to 90 minutes. This approach, adapted from the HIPEC technique used in peritoneal mesothelioma, aims to destroy microscopic residual tumor cells. As of 2024, HITHOC via VATS remains investigational, with ongoing trials at institutions including Memorial Sloan Kettering Cancer Center and the University of Pennsylvania.

For patients whose disease is too advanced for resection, VATS still offers palliative benefit. Talc pleurodesis performed thoracoscopically is more effective than bedside pleurodesis via chest tube, according to a landmark 2011 Cochrane review, with success rates of 80% to 90% for preventing effusion recurrence. Controlling effusion can meaningfully relieve breathlessness and improve a patient's ability to tolerate other treatments.

VATS itself doesn't change the underlying prognosis of mesothelioma, which remains poor regardless of treatment approach. Median survival for pleural mesothelioma ranges from 12 to 21 months depending on stage, subtype, and treatment received, according to the American Cancer Society's 2023 statistics. What VATS does affect is the speed and accuracy of diagnosis, the feasibility of multimodal treatment, and the quality of life during treatment.

Faster diagnosis enabled by VATS means that systemic therapy, most commonly the combination of cisplatin and pemetrexed approved by the FDA in 2004, can begin sooner. In mesothelioma, where disease can progress quickly, weeks matter. Patients diagnosed via VATS biopsy may reach treatment decisions faster than those who undergo multiple inconclusive needle biopsies over several months.

Postoperative recovery data consistently favor VATS over open surgery. A 2020 retrospective study from the Brigham and Women's Hospital thoracic surgery program found that patients who underwent minimally invasive P/D had a 30-day mortality rate of under 2%, compared to 3% to 5% historically reported for open EPP. Shorter recovery also means patients are more likely to be well enough to pursue adjuvant chemotherapy or participate in clinical trials, which can extend survival.

If your care team has recommended VATS, knowing what to expect before, during, and after the procedure can reduce anxiety and help you prepare practically. The preoperative period typically involves pulmonary function testing, cardiac evaluation, blood work, and imaging review. You'll be asked to stop eating and drinking after midnight before surgery and to discontinue blood thinners like warfarin or clopidogrel several days in advance, per your surgeon's specific instructions.

After surgery, most patients wake up with one or two small chest tubes in place to drain any residual fluid or air. These are usually removed within 24 to 48 hours if drainage is minimal. Pain is managed with a combination of oral analgesics, anti-inflammatory medications, and sometimes a short course of IV pain medication. The small incision sites heal quickly, and most patients are walking the day after surgery.

Returning home doesn't mean recovery is complete. You'll likely be advised to avoid lifting anything heavier than 10 pounds for two to four weeks, to watch the incision sites for signs of infection, and to attend a follow-up appointment within one to two weeks. Breathlessness during activity is common for the first few weeks as the lung re-expands and adjusts. Pulmonary rehabilitation, a structured exercise and breathing program, can help accelerate functional recovery and is increasingly recommended for mesothelioma patients after thoracic surgery.

Emotional recovery is part of the process, too. VATS is often the procedure that confirms a mesothelioma diagnosis, which means the days following surgery can be filled with difficult conversations and decisions. Connecting with a patient navigator, social worker, or mesothelioma support group during this period can make a significant difference. Organizations like the Mesothelioma Applied Research Foundation offer peer mentorship programs that connect newly diagnosed patients with others who have been through the same experience.